Healome's Smart Eye-Drop Matrix: A UK Biotech Breakthrough for Vision

BIRMINGHAM, ENGLAND – July 07, 2026 – For the 350 million people worldwide suffering from dry eye disease, the daily ritual of administering eye drops can feel like a frustrating exercise in futility. The vast majority of a conventional drop is blinked away within minutes, necessitating relentless reapplication—sometimes up to 20 times a day—and leading to treatment adherence rates plummeting as low as 20%. This fundamental flaw in ocular drug delivery has created a multi-billion-dollar market bottleneck. Now, a University of Birmingham spinout believes it has the solution.

Healome Therapeutics has closed an oversubscribed £2 million seed round to advance its proprietary eye-drop matrix technology, a platform poised to transform treatment for a vast range of ocular surface diseases. The financing, led by deep-tech investor Empirical Ventures, signals significant confidence in a technology that moves beyond incremental improvement to offer a category-defining shift in how we treat the surface of the eye.

The Science of a Smarter Drop

At the heart of Healome's innovation is a fluid-gel that performs a remarkable transformation. It behaves like a simple liquid in the bottle but, upon contact with the eye's surface, instantly restructures to form a clear, protective, and lubricated matrix. This transparent “therapeutic bandage” is designed to remain on the eye for an extended period, resisting the rapid clearance that plagues conventional treatments. This prolonged residence time is the key to unlocking better outcomes.

"Using our matrix to extend residence time of novel and existing therapeutics opens the door to reduced dosing, better adherence and ultimately improved outcomes across a range of indications," said Dr. Richard Williams, CEO of Healome Therapeutics. "This financing lets us drive the platform toward the clinic."

Crucially, the platform's elegance lies in its simplicity and manufacturing readiness. The matrix is built from established pharmaceutical- and food-grade polymers, structured into proprietary architectures covered by five patent families. This avoids the complex chemical modifications that often create regulatory and manufacturing hurdles for novel drug formulations. Preclinical studies have already yielded impressive results, showing the matrix, when used to deliver an anti-scarring biologic, promoted rapid corneal healing and reduced scarring in severely injured corneas.

A Platform for a $12 Billion Market

The immediate target, the $5 billion global dry eye market, represents only the entry point. The broader market for ocular surface diseases—encompassing inflammation, corneal injuries, and chronic drug delivery—exceeds $12 billion. By solving the core problem of drug retention, Healome’s platform can be used to deliver a wide array of therapeutics, from small molecules to complex biologics, more effectively.

This versatility is what caught the eye of investors. Johnathan Matlock, Co-Founder and General Partner at lead investor Empirical Ventures, stated, "Healome targets a quantifiable bottleneck - drug residence time on the ocular surface - with a manufacturing-friendly approach built on well-characterised polymers. The approach and the data... is what convinced us this is a category-defining platform rather than an incremental formulation play, with credible read-across from dry eye through to rare ocular diseases."

This is not merely about making existing drugs better; it's about enabling new therapies that were previously unviable due to the delivery challenge. For a field reliant on patient compliance, a technology that can reduce a demanding dosing schedule to just once or twice a day represents a monumental leap forward in quality of life and clinical efficacy.

A Beacon of Hope for Rare Disease

The most profound potential of Healome's technology may lie in its application for rare diseases, a focus underscored by the participation of DEBRA Research and Cure EB in the funding round. These organizations are dedicated to fighting Epidermolysis Bullosa (EB), a devastating genetic condition affecting half a million people globally. While known for causing fragile, blistering skin, its impact on the eyes is equally severe.

Up to 20% of EB patients suffer from ocular complications, including recurrent, painful corneal abrasions, chronic inflammation, and a high risk of sight-threatening scarring. As highlighted in the Netflix documentary Matter of Time, the unmet needs are immense. For these patients, Healome’s matrix offers the promise of a gentle, patient-friendly therapy that can both protect the fragile ocular surface and deliver healing agents to prevent scarring.

"For many people living with EB, the condition not only affects the skin but also the eyes," explained Dr. Christoph Coch, Managing Director at DEBRA Research. "As there are currently no specific treatments for these ocular complications, we look forward to supporting Healome in their effort to develop patient-friendly and effective therapeutic approaches in this area."

The Path to the Clinic

Born from over 80 years of combined experience in biomaterials and regenerative medicine at the University of Birmingham's Healthcare Technologies Institute, Healome represents a powerful example of UK academic research translating into high-impact commercial innovation. The support from a syndicate including Empirical Ventures, SFC Capital, Oshen Bio, and patient-focused foundations provides a robust financial and strategic runway.

The £2 million in proceeds will be used to finalize pre-clinical development, scale up manufacturing, and begin critical regulatory engagement with the MHRA in the UK and the FDA in the United States. With these milestones in sight, the company is targeting its first-in-human studies for 2027. With a clear path to the clinic and a technology that addresses a fundamental flaw in ocular medicine, Healome Therapeutics is now positioned to prove that a simple drop can deliver a profound impact.